Ireland's central source for Open Access health research
Lenus, the Irish Health Research repository is the leading source for Irish research in health and social care. The Lenus collections include peer reviewed journal articles, grey literature, dissertations, reports and conference presentations. Lenus contains the publications of the Irish Health Service Executive (HSE) and the collected research output of over 130 health organisations past and present are all freely accessible.
Submit Your Research to Lenus
If you are an Irish researcher or have conducted research in an Irish institution or health organisation, you can add your published research to Lenus. Submitted articles must be available in Open Access format or the publisher's policy must permit author self archiving. Advice on Open Access publishing and publishers' policies is available on the 'Open Access Publishing Guide' and 'Publishers' policies' pages available on the left-hand menu.
Authors and researchers – have you applied for an ORCID?
ORCIDs are a form of persistent unique identifier that gather all your published research together and link it unambiguously with you. Having an ORCID means eliminating confusion with similarly-named authors, and allows you to list all past affiliations, funding details and publications. Click here to get your free ORCID today.
HSE Open Access Research Awards 2022
The annual HSE Open Access Awards were announced on 5th December 2022. This year the winners were in the following categories:
Acute Care & Hospitals
Response to treatment and outcomes of infantile spasms in Down syndrome.
Susan Harvey and colleagues
Community & Social Care
The duration of infectiousness of individuals infected with SARS-CoV-2.
Kieran Walsh and colleagues
Mental Health & Disabilities
Brief psychological interventions in face-to-face and telehealth formats: a comparison of outcomes in a naturalistic setting
Padraig Collins and colleagues
Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
John Smith and colleagues
Climate or Environmental Health
How to Irish Hospitals manage the core components of critical infrastructure resilience, and how can this be developed further to mitigate the impact of extreme weather events?
Special Innovation Award Winner
Flood hydrometeorology and gastroenteric infection: The Winter 2015-2016 flood event in the Republic of Ireland
Martin Boudou and colleagues
An Evaluation of the Impact of a Multicomponent Stop Smoking Intervention in an Irish Prison
Andrea Bowe and colleagues
Congratulations to all our winners, and to all who entered their research for the Awards. And a sincere thanks to our judges, who generously lent us their expertise.
Tweets by LenusHSE Follow @LenusHSE
Communities in Lenus
Select a community to browse its collections.
An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer.This was a single arm, non-interventional, prospective study. The primary endpoint was to determine the rate of neutropenia defined as ANC of < 1.0 × 109/L, during four cycles of dose dense AC with lipegfilgrastim support. The secondary endpoints were the incidence of febrile neutropenia, (temperature > 38 °C and ANC < 1.0 × 109/L), treatment delays, premature treatment cessation and toxicity.
Improved Strength Recovery and Reduced Fatigue with Suppressed Plasma Myostatin Following Supplementation of a Hydrolysate, in a Healthy Male Population.Delayed onset muscle soreness (DOMS) due to intense physical exertion can negatively impact contractility and performance. Previously, NPN_1 (PeptiStrong™), a Vicia faba hydrolysate derived from a protein concentrate discovered through artificial intelligence (AI), was preclinically shown to help maintain muscle health, indicating the potential to mediate the effect of DOMS and alter molecular markers of muscle damage to improve recovery and performance. A randomised double-blind placebo-controlled trial was conducted on 30 healthy male (30-45 years old) volunteers (NCT05159375). Following initial strength testing on day 0, subjects were administered either placebo or NPN_1 (2.4 g/day). On day 14, DOMS was induced using resistance exercise. Strength recovery and fatigue were measured after 48 and 72 h. Biomarker analysis was performed on blood samples collected prior to DOMS induction and 0, 2, 48 and 72 h post-DOMS induction. NPN_1 supplementation significantly improved strength recovery compared to placebo over the 72 h period post-resistance exercise (p = 0.027), measured by peak torque per bodyweight, but not at individual timepoints. Muscle fatigue was significantly reduced over the same 72 h period (p = 0.041), as was myostatin expression (p = 0.006). A concomitant increase in other acute markers regulating muscle protein synthesis, regeneration and myoblast differentiation was also observed. NPN_1 significantly improves strength recovery and restoration, reduces fatigue and positively modulates alterations in markers related to muscle homeostasis.